Seminars in Nephrology
Volume 25, Issue 4 , Pages 227-235 , July 2005

Therapeutic Controversies in Hypertension

  • Franz H. Messerli

      Affiliations

    • St. Lukes-Roosevelt Hospital Center, New York, NY
    • Internal Medicine D and Hypertension Unit, The Chaim Sheba Medical Center, Tel-Hashomer, Israel
    • Corresponding Author InformationAddress reprint requests to Franz H. Messerli, MD, St. Lukes-Roosevelt Hospital Center, New York, NY 10019
    • ,
  • Ehud Grossman

      Affiliations

    • St. Lukes-Roosevelt Hospital Center, New York, NY
    • Internal Medicine D and Hypertension Unit, The Chaim Sheba Medical Center, Tel-Hashomer, Israel

References 

  1. Veterans Administration Cooperative Study Group on Antihypertensive Agents . Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg . JAMA . 1967;202:1028–1034
  2. Veterans Administration Cooperative Study Group on Antihypertensive Agents . Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg . JAMA . 1970;213:1143–1152
  3. SHEP Cooperative Research Group . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP) . JAMA . 1991;265:3255–3264
  4. MRC Working Party . Medical Research Council trial of treatment of hypertension in older adults (Principal results) . BMJ . 1992;304:405–412
  5. Warram JH , Laffel LM , Valsania P , et al.   Excess mortality associated with diuretic therapy in diabetes mellitus . Arch Intern Med . 1991;151:1350–1356
  6. Curb JD , Pressel SL , Cutler JA , et al.   Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group . JAMA . 1996;276:1886–1892
  7. Mancia G , Brown M , Castaigne A , et al.   Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT) . Hypertension . 2003;41:431–436
  8. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group . The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) . JAMA . 2002;288:2981–2997
  9. Carlsen JE , Kober L , Torp-Pedersen C , et al.   Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects . BMJ . 1990;300:975–978
  10. Siscovick DS , Raghunathan TE , Psaty BM , et al.   Diuretic therapy for hypertension and the risk of primary cardiac arrest . N Engl J Med . 1994;330:1852–1857
  11. Pitt B , Remme W , Zannad F , et al.   Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction . N Engl J Med . 2003;348:1309–1321
  12. Pitt B , Zannad F , Remme WJ , et al.   The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators . N Engl J Med . 1999;341:709–717
  13. Wing LM , Reid CM , Ryan P , et al.   A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly . N Engl J Med . 2003;348:583–592
  14. Multiple Risk Factor Intervention Trial Group . Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial . Circulation . 1990;82:1616–1628
  15. Hansson L , Lindholm LH , Ekbom T , et al.   Randomised trial of old and new antihypertensive drugs in elderly patients (Cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study) . Lancet . 1999;354:1751–1756
  16. Hansson L , Lindholm LH , Niskanen L , et al.   Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension (The Captopril Prevention Project (CAPPP) randomised trial) . Lancet . 1999;353:611–616
  17. Guidelines Committee . 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension . J Hypertens . 2003;21:1011–1053
  18. Chobanian AV , Bakris GL , Black HR , et al.   The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (The JNC 7 report) . JAMA . 2003;289:2560–2572
  19. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure . Arch Intern Med . 1997;157:2413–2446
  20. Messerli FH , Grossman E , Goldbourt U . Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review . JAMA . 1998;279:1903–1907
  21. Lever AF , Brennan PJ . MRC trial of treatment in elderly hypertensives . Clin Exp Hypertens . 1993;15:941–952
  22. Eriksson S , Olofsson B-O , Wester P-O  TEST Study Group . Atenolol in secondary prevention after stroke . Cerebrovasc Dis . 1995;5:21–25
  23. Dutch TIA Trial Study Group . Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke . Stroke . 1993;24:543–548
  24. Dahlof B , Devereux RB , Kjeldsen SE , et al.   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) (A randomised trial against atenolol) . Lancet . 2002;359:995–1003
  25. Lindholm LH , Ibsen H , Dahlof B , et al.   Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) (A randomised trial against atenolol) . Lancet . 2002;359:1004–1010
  26. Hoes AW , Grobbee DE , Lubsen J , et al.   Diuretics, beta-blockers, and the risk for sudden cardiac death in hypertensive patients . Ann Intern Med . 1995;123:481–487
  27. Dahlof B , Lindholm LH , Hansson L , et al.   Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) . Lancet . 1991;338:1281–1285
  28. Kostis JB , Berge KG , Davis BR , et al.   Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP) . Am J Hypertens . 1995;8:1147–1153
  29. Coope J , Warrender TS . Randomised trial of treatment of hypertension in elderly patients in primary care . BMJ . 1986;293:1145–1151
  30. Medical Research Council Working Party . MRC trial of treatment of mild hypertension (Principal results) . BMJ . 1985;291:97–104
  31. The IPPPSH Collaborative Group . Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol (The International Prospective Primary Prevention Study in Hypertension (IPPPSH)) . J Hypertens . 1985;3:379–392
  32. Wilhelmsen L , Berglund G , Elmfeldt D , et al.   Beta-blockers versus diuretics in hypertensive men (Main results from the HAPPHY trial) . J Hypertens . 1987;5:561–572
  33. The National High Blood Pressure Education Program Working Group . Primary prevention with metoprolol in patients with hypertension (letter) . JAMA . 1988;260:1713–1716
  34. National High Blood Pressure Education Program Working Group report on hypertension in diabetes . Hypertension . 1994;23:145–160
  35. UK Prospective Diabetes Study Group . Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 39) . BMJ . 1998;317:713–720
  36. Poole-Wilson PA , Swedberg K , Cleland JG , et al.   Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET) (Randomised controlled trial) . Lancet . 2003;362:7–13
  37. GEMINI study . Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension (a randomized controlled trial) . JAMA . 2004;292:2227–2236
  38. Pahor M , Guralnik JM , Corti MC , et al.   Long-term survival and use of antihypertensive medications in older persons . J Am Geriatr Soc . 1995;43:1191–1197
  39. Borhani NO , Mercuri M , Borhani PA , et al.   Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial . JAMA . 1996;276:785–791
  40. Furberg CD , Psaty BM , Meyer JV . Nifedipine. Dose-related increase in mortality in patients with coronary heart disease . Circulation . 1995;92:1326–1331
  41. Psaty BM , Heckbert SR , Koepsell TD , et al.   The risk of myocardial infarction associated with antihypertensive drug therapies . JAMA . 1995;274:620–625
  42. Pahor M , Guralnik JM , Salive ME , et al.   Do calcium channel blockers increase the risk of cancer? . Am J Hypertens . 1996;9:695–699
  43. Fitzpatrick AL , Daling JR , Furberg CD , et al.   Use of calcium channel blockers and breast carcinoma risk in postmenopausal women . Cancer . 1997;80:1438–1447
  44. Lindholm LH , Anderson H , Ekbom T , et al.   Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2 (A 5-year, prospective, randomised, controlled trial) . Lancet . 2001;358:539–544
  45. Brown MJ , Palmer CR , Castaigne A , et al.   Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study (Intervention as a Goal in Hypertension Treatment (INSIGHT)) . Lancet . 2000;356:366–372
  46. Hansson L , Zanchetti A , Carruthers SG , et al.  HOT Study Group   Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension (Principal results of the Hypertension Optimal Treatment (HOT) randomised trial) . Lancet . 1998;351:1755–1762
  47. Staessen JA , Fagard R , Thijs L , et al.   Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators . Lancet . 1997;350:757–764
  48. Hansson L , Hedner T , Lund-Johansen P , et al.   Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension (The Nordic Diltiazem (NORDIL) study) . Lancet . 2000;356:359–365
  49. Agodoa LY , Appel L , Bakris GL , et al.   Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis (A randomized controlled trial) . JAMA . 2001;285:2719–2728
  50. Lewis EJ , Hunsicker LG , Clarke WR , et al.   Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes . N Engl J Med . 2001;345:851–860
  51. Berl T , Hunsicker LG , Lewis JB , et al.   Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy . Ann Intern Med . 2003;138:542–549
  52. Julius S , Kjeldsen SE , Weber M , et al.   Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine (The VALUE randomised trial) . Lancet . 2004;363:2022–2031
  53. Sowers JR , Epstein M , Frohlich ED . Diabetes, hypertension, and cardiovascular disease (An update) . Hypertension . 2001;37:1053–1059
  54. Grossman E , Messerli FH , Goldbourt U . High blood pressure and diabetes mellitus (Are all antihypertensive drugs created equal?) . Arch Intern Med . 2000;160:2447–2452
  55. Parving HH , Smidt UM . Hypotensive therapy reduces microvascular albumin leakage in insulin-dependent diabetic patients with nephropathy . Diabet Med . 1986;3:312–315
  56. Parving HH , Andersen AR , Smidt UM , et al.   Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy . Lancet . 1983;1:1175–1179
  57. UK Prospective Diabetes Study Group . Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38) . BMJ . 1998;317:703–713
  58. Estacio RO , Jeffers BW , Hiatt WR , et al.   The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension . N Engl J Med . 1998;338:645–652
  59. Tatti P , Pahor M , Byington RP , et al.   Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM . Diabetes Care . 1998;21:597–603
  60. Tuomilehto J , Rastenyte D , Birkenhager WH , et al.   Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators . N Engl J Med . 1999;340:677–684
  61. Grossman E , Messerli FH . Are calcium antagonists beneficial in diabetic patients with hypertension? . Am J Med . 2004;116:44–49
  62. Pfeffer MA , Braunwald E , Moye LA , et al.   Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators . N Engl J Med . 1992;327:669–677
  63. Pfeffer MA , Lamas GA , Vaughan DE , et al.   Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction . N Engl J Med . 1988;319:80–86
  64. The CONSENSUS Trial Study Group . Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) . N Engl J Med . 1987;316:1429–1435
  65. The SOLVD Investigators . Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure . N Engl J Med . 1991;325:293–302
  66. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators . Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure . Lancet . 1993;342:821–828
  67. Viberti G , Mogensen CE , Groop LC , et al.   Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group . JAMA . 1994;271:275–279
  68. Lewis EJ , Hunsicker LG , Bain RP , et al.   The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group . N Engl J Med . 1993;329:1456–1462
  69. Ruggenenti P , Perna A , Gherardi G , et al.   Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria . Lancet . 1999;354:359–364
  70. Ruggenenti P , Perna A , Gherardi G , et al.   Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy . Lancet . 1998;352:1252–1256
  71. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) . Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy . Lancet . 1997;349:1857–1863
  72. Ravid M , Savin H , Jutrin I , et al.   Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients . Ann Intern Med . 1993;118:577–581
  73. Heart Outcomes Prevention Evaluation Study Investigators . Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus (Results of the HOPE study and MICRO-HOPE substudy) . Lancet . 2000;355:253–259
  74. Fox KM  EURopean Trial On Reduction of Cardiac Events With Perindopril in Stable Coronary Artery Disease Investigators . Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease (Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)) . Lancet . 2003;362:782–788
  75. Yusuf S , Sleight P , Pogue J , et al.   Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators . N Engl J Med . 2000;342:145–153
  76. PROGRESS Collaborative Group . Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack . Lancet . 2001;358:1033–1041
  77. Messerli FH , White WB , Staessen JA . If only cardiologists did properly measure blood pressure. Blood pressure recordings in daily practice and clinical trials . J Am Coll Cardiol . 2002;40:2201–2203
  78. Svensson P , de Faire U , Sleight P , et al.   Comparative effects of ramipril on ambulatory and office blood pressures (A HOPE substudy) . Hypertension . 2001;38:E28–E32
  79. Gillis JC , Markham A . Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension . Drugs . 1997;54:885–902
  80. Goa KL , Wagstaff AJ . Losartan potassium (A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension) . Drugs . 1996;51:820–845
  81. Markham A , Goa KL . Valsartan. A review of its pharmacology and therapeutic use in essential hypertension . Drugs . 1997;54:299–311
  82. Brenner BM , Cooper ME , de Zeeuw D , et al.  RENAAL Study Investigators   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy . N Engl J Med . 2001;345:861–869
  83. Lithell H , Hansson L , Skoog I , et al.  SCOPE Study Group   The Study on Cognition and Prognosis in the Elderly (SCOPE) (Principal results of a randomized double-blind intervention trial) . J Hypertens . 2003;21:875–886
  84. Pitt B , Poole-Wilson PA , Segal R , et al.   Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure (Randomised trial-the Losartan Heart Failure Survival Study ELITE II) . Lancet . 2000;355:1582–1587
  85. Maggioni AP , Anand I , Gottlieb SO , et al.  Val-Heft Investigators (Valsartan Heart Failure Trial)   Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors . J Am Coll Cardiol . 2002;40:1414–1421
  86. Cohn JN , Tognoni G  Valsartan Heart Failure Trial Investigators . A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure . N Engl J Med . 2001;345:1667–1675
  87. Yusuf S , Pfeffer MA , Swedberg K , et al.  CHARM Investigators and Committees   Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction (The CHARM-Preserved Trial) . Lancet . 2003;362:777–781
  88. Granger CB , McMurray JJ , Yusuf S , et al.  CHARM Investigators and Committees   Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors (The CHARM-Alternative trial) . Lancet . 2003;362:772–776
  89. McMurray JJ , Ostergren J , Swedberg K , et al.  CHARM Investigators and Committees   Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors (The CHARM-Added trial) . Lancet . 2003;362:767–771
  90. Pfeffer MA , Swedberg K , Granger CB , et al.  CHARM Investigators and Committees   Effects of candesartan on mortality and morbidity in patients with chronic heart failure (The CHARM-Overall programme) . Lancet . 2003;362:759–766
  91. Grossman E , Messerli FH , Neutel JM . Angiotensin II receptor blockers (Equal or preferred substitutes for ACE inhibitors?) . Arch Intern Med . 2000;160:1905–1911
  92. Dickstein K , Kjekshus J  OPTIMAAL Steering Committee of the OPTIMAAL Study Group . Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan . Lancet . 2002;360:752–760
  93. Nakao N , Yoshimura A , Morita H , et al.   Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE) (A randomised controlled trial) . Lancet . 2003;361:117–124
  94. Pool JL . Effects of doxazosin on coronary heart disease risk factors in the hypertensive patient . Br J Clin Pract Suppl . 1994;74:8–12
  95. Grimm RH , Flack JM , Grandits GA , et al.   Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group . JAMA . 1996;275:1549–1556
  96. ALLHAT Collaborative Research Group . Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone (The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)) . JAMA . 2000;283:1967–1975
  97. Messerli FH . Implications of discontinuation of doxazosin arm of ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial . Lancet . 2000;355:863–864
  98. Lewis PJ , Kohner EM , Petrie A , et al.   Deterioration of glucose tolerance in hypertensive patients on prolonged diuretic treatment . Lancet . 1976;1:564–566
  99. Murphy MB , Lewis PJ , Kohner E , et al.   Glucose intolerance in hypertensive patients treated with diuretics; a fourteen-year follow-up . Lancet . 1982;2:1293–1295
  100. Hansson L , Lindholm LH , Ekbom T , et al.  STOP-Hypertension-2 Study Group   Randomised trial of old and new antihypertensive drugs in elderly patients (Cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study) . Lancet . 1999;354:1751–1756
  101. Yusuf S , Gerstein H , Hoogwerf B , et al.  HOPE Study Investigators   Ramipril and the development of diabetes . JAMA . 2001;286:1882–1885
  102. Wing LM , Reid CM , Ryan P , et al.  Second Australian National Blood Pressure Study Group   A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly . N Engl J Med . 2003;348:583–592
  103. Pepine CJ , Handberg EM , Cooper-DeHoff RM , et al.  INVEST Investigators   A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial . JAMA . 2003;290:2805–2816
  104. Lindholm LH , Persson M , Alaupovic P , et al.   Metabolic outcome during 1 year in newly detected hypertensives (Results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study)) . J Hypertens . 2003;21:1563–1574
  105. Opie LH , Schall R . Old antihypertensives and new diabetes . J Hypertens . 2004;22:1453–1458 (Review)
  106. Conn JW . Hypertension, the potassium ion and impaired carbohydrate tolerance . N Engl J Med . 1965;273:1135–1143
  107. Fajans SS , Floyd JC , Knopf RF , et al.   Benzothiadiazine suppression of insulin release from normal and abnormal islet tissue in man . J Clin Invest . 1966;45:481–492
  108. Helderman JH , Elahi D , Andersen DK , et al.   Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium . Diabetes . 1983;32:106–111
  109. Messerli FH . ALLHAT, or the soft science of the secondary end point . Ann Intern Med . 2003;139:777–780
  110. Verdecchia P , Reboldi G , Angeli F , et al.   Adverse prognostic significance of new diabetes in treated hypertensive subjects . Hypertension . 2004;43:963–969
  111. Alderman MH , Cohen H , Madhavan S . Diabetes and cardiovascular events in hypertensive patients . Hypertension . 1999;33:1130–1134
  112. Shamiss A , Carrol J , Peleg E , et al.   Enalapril with and without hydrochlorothiazide (Effects on insulin sensitivity and metabolic abnormalities of NIDDM hypertensive patients) . Am J Hypertens . 1995;8:276–281
  113. Grossman E , Messerli FH , Goldbourt U . Does diuretic therapy increase the risk of renal cell carcinoma? . Am J Cardiol . 1999;83:1090–1093

PII: S0270-9295(05)00032-X

doi: 10.1016/j.semnephrol.2005.02.007

Seminars in Nephrology
Volume 25, Issue 4 , Pages 227-235 , July 2005

Article Tools